OncoMatch/Clinical Trials/NCT05182944
A Study of Perioperative Camrelizumab Combined With Chemotherapy in Patients With Resectable ESCC
Is NCT05182944 recruiting? Yes, currently enrolling (May 2026). This Phase 2 trial studies multiple treatments including A：non-pCR patients and B：non-pCR patients for esophageal cancer.
Treatment: A：non-pCR patients · B：non-pCR patients · A：pCR patients · B：pCR patients — The purpose of this study is to observe and evaluate the efficacy and safety of camrelizumab combined with albumin paclitaxel and cisplatin as perioperative treatment of advanced esophageal squamous cell.
Check if I qualifyExtracted eligibility criteria
Cancer type
Esophageal Carcinoma
Biomarker criteria
Required: PD-L1 (CD274) any tested (testing required; no eligibility threshold specified)
Disease stage
Required: Stage T1B-2N+M0, T3-4AN+/-M0 (AJCC/UICC TNM staging system 8th edition)
clinical stage is T1b-2N+M0 or T3-4aN+/-M0 (AJCC/UICC TNM staging system 8th edition)
Performance status
ECOG 0–1(Restricted strenuous activity)
Prior therapy
Cannot have received: anti-tumor therapy
Exception: Chinese patent medicines or Chinese herbal medicines stopped for more than 7 days
Previously received anti-tumor therapy for the primary disease (including surgery, chemotherapy, targeted therapy, immunotherapy, anti-angiogenesis therapy, radiotherapy, radiofrequency ablation, etc.) and other research treatments, except for Chinese patent medicines or Chinese herbal medicines stopped for more than 7 days
Lab requirements
Blood counts
WBC ≥3.0 × 10^9/L, ANC ≥1.5 × 10^9/L, PLT ≥100×10^9/L, HGB ≥90 g/L, no blood transfusion or other hematopoietic factor treatment for the previous 14 days
Kidney function
Serum creatinine ≤1.0×ULN, creatinine clearance ≥60 mL/min (Cockcroft-Gault formula)
Liver function
ALT, AST, ALP ≤2.5×ULN; TBIL ≤1.5×ULN; Albumin ≥30g/L; Child-Pugh grade 5-6 points
Cardiac function
Heart function: normal or grade I
Important organ functions: a) Heart function: normal or grade I; b) Lung function: FEV1>1.2L, FEV1% >40%; c) Liver function: Child-Pugh grade 5-6 points; ALT, AST, ALP ≤2.5×ULN; TBIL ≤1.5×ULN; Albumin ≥30g/L; Serum creatinine ≤1.0×ULN, creatinine clearance ≥60 mL/min (Cockcroft-Gault formula); WBC ≥3.0 × 10^9/L, ANC ≥1.5 × 10^9/L, PLT ≥100×10^9/L, HGB ≥90 g/L, no blood transfusion or other hematopoietic factor treatment for the previous 14 days
Structured fields extracted by AI. May contain errors — verify against the official protocol.
Could you qualify for this trial?
Enter your biomarker results to see how this trial's eligibility criteria match your specific cancer profile.
Check if I qualify